Last10K.com

Receptos, Inc. (RCPT) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Receptos, Inc.

CIK: 1463729 Ticker: RCPT

Exhibit 99.1

 

Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results

 

-  Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -

 

- Phase 3 trial of RPC1063 in relapsing multiple sclerosis has begun enrolling patients -

 

-  Top-line data from Phase 2 trial of RPC1063 in ulcerative colitis expected in mid-2014 -

 

-  Conference Call Today at 5 p.m. Eastern Time -

 

San Diego, CA, March 5, 2014 — 

Receptos, Inc. (Nasdaq: RCPT) today provided development program updates and announced financial results for the fourth quarter and year ended December 31, 2013.

 

“The data from the interim analysis of the Phase 2 portion of our RADIANCE trial was consistent with our differentiation thesis, and provided support to continue to advance the program,” said Faheem Hasnain, President and Chief Executive Officer of Receptos.  “Our initiation of the Phase 3 portion of our RADIANCE trial positions RPC1063 as the potential next-to-market oral agent for the treatment of relapsing multiple sclerosis.  We look forward to mid-2014 for the top-line results of the Phase 2 portion of RADIANCE, as well as top-line results of TOUCHSTONE, our Phase 2 study of RPC1063 in ulcerative colitis, and continued progress with our pipeline programs.”

 

Receptos is developing RPC1063, a small molecule sphingosine 1-phosphate 1 (S1P1) receptor modulator administered orally for immunology indications.  The Company has initiated a Phase 3 trial of RPC1063 in relapsing multiple sclerosis (RMS) and is currently conducting separate Phase 2 trials in RMS and ulcerative colitis (UC), with top-line data expected for both trials in mid-2014.  The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an immune-mediated orphan disease, eosinophilic esophagitis (EoE), and is in preclinical development of oral, small molecule, positive allosteric modulators of the GLP-1 receptor for the treatment of Type 2 diabetes.

 

Development Program Updates

RPC1063 in Relapsing Multiple Sclerosis

·                  In Q4 2013, Receptos completed enrollment in the Phase 2 portion of RADIANCE, its Phase 2/3 trial of RPC1063 in RMS.  The primary objective of the Phase 2 portion of the study is to demonstrate the superior clinical efficacy of RPC1063 compared to placebo as measured by a reduction in the cumulative number of total gadolinium-enhancing lesions determined by MRI from week 12 to week 24 of study treatment. Top-line data for this trial is expected in mid-2014.

·                  In Q4 2013, Receptos completed a pre-planned interim analysis of the Phase 2 portion of RADIANCE.  The interim analysis focused on several potential product attributes that may be important for differentiation from other S1P receptor modulators on the market or in development. These included the overall adverse event profile; cardiovascular profile; liver enzyme effects; and preliminary clinical activity and reduction in lymphocyte count.

·                  In December 2013, based on these interim results and with the recommendation of the study’s Data Monitoring Committee, the Company initiated enrollment of the Phase 3 portion of RADIANCE   This is a randomized, double-blind, double-dummy study designed to compare 0.5 mg and 1.0 mg of orally administered RPC1063 against injected interferon beta-1a (Avonex®) in 1,200 patients with RMS. It is being conducted under a Special Protocol Assessment (SPA) with the FDA.

 


The following information was filed by Receptos, Inc. (RCPT) on Wednesday, March 5, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Receptos, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Receptos, Inc..

Continue

Assess how Receptos, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Receptos, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity/ (deficit)
Consolidated Statements Of Operations And Comprehensive Loss
Balance Sheet Details
Balance Sheet Details (details)
Balance Sheet Details (tables)
Collaborative Arrangements
Collaborative Arrangements (details)
Collaborative Arrangements (tables)
Commitments And Contingencies
Commitments And Contingencies (details 2)
Commitments And Contingencies (details)
Convertible Preferred Stock
Convertible Preferred Stock (details)
Description Of Business
Description Of Business (details)
Employee Benefits
Income Taxes
Income Taxes (details 2)
Income Taxes (details)
Income Taxes (tables)
Selected Quarterly Financial Information (unaudited)
Selected Quarterly Financial Information (unaudited) (details)
Selected Quarterly Financial Information (unaudited) (tables)
Short-term Investments
Short-term Investments (details 2)
Short-term Investments (details)
Short-term Investments (tables)
Stock-based Compensation And Equity Plans
Stock-based Compensation And Equity Plans (details 2)
Stock-based Compensation And Equity Plans (details 3)
Stock-based Compensation And Equity Plans (details)
Stock-based Compensation And Equity Plans (tables)
Stockholders' Equity
Stockholders' Equity (details)
Subsequent Events (unaudited)
Subsequent Events (unaudited) (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details 2)
Summary Of Significant Accounting Policies (details 3)
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Term Loan And Security Agreement
Term Loan And Security Agreement (details)
Term Loan And Security Agreement (tables)
Ticker: RCPT
CIK: 1463729
Form Type: 10-K Annual Report
Accession Number: 0001047469-14-001911
Submitted to the SEC: Thu Mar 06 2014 4:43:31 PM EST
Accepted by the SEC: Thu Mar 06 2014
Period: Tuesday, December 31, 2013
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rcpt/0001047469-14-001911.htm